Merel van Nuland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8025540/publications.pdf

Version: 2024-02-01

932766 1058022 15 215 10 14 citations h-index g-index papers 15 15 15 298 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Dosing Therapeutic Radiopharmaceuticals in Obese Patients. International Journal of Molecular Sciences, 2022, 23, 818.	1.8	4
2	Bioanalytical LC–MS/MS validation of therapeutic drug monitoring assays in oncology. Biomedical Chromatography, 2020, 34, e4623.	0.8	13
3	Exposureâ€"response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 244-251.	2.0	19
4	Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. Clinical Pharmacology in Drug Development, 2020, 9, 929-937.	0.8	2
5	Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology. Clinical Pharmacokinetics, 2019, 58, 299-308.	1.6	41
6	Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clinical Genitourinary Cancer, 2019, 17, e893-e896.	0.9	0
7	Exposureâ€Response Assessment of Enzalutamide and Its Major Metabolites in a Realâ€World Cohort of Patients with Metastatic Castrationâ€Resistant Prostate Cancer. Pharmacotherapy, 2019, 39, 1137-1145.	1.2	9
8	Predictive Value of Microdose Pharmacokinetics. Clinical Pharmacokinetics, 2019, 58, 1221-1236.	1.6	16
9	LC–MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide. Journal of Pharmaceutical and Biomedical Analysis, 2019, 170, 161-168.	1.4	16
10	Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis. Clinical Genitourinary Cancer, 2019, 17, e383-e386.	0.9	7
11	Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1106-1107, 26-34.	1.2	22
12	Ultra-sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine in human plasma for a microdose clinical trial. Journal of Pharmaceutical and Biomedical Analysis, 2018, 151, 25-31.	1.4	15
13	Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. Breast Cancer Research and Treatment, 2018, 172, 143-150.	1.1	12
14	Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma. Therapeutic Drug Monitoring, 2017, 39, 243-251.	1.0	28
15	An LC–MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1068-1069, 119-124.	1.2	11